NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-.
CASRN: 1346452-25-2
Drug Levels and Effects
Summary of Use during Lactation
No information is available on the clinical use of enfortumab vedotin during breastfeeding. Because enfortumab is a large protein molecule with a molecular weight of about 152,000 Da, the amount in milk is likely to be very low. It is also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal. Vedotin (monomethyl auristatin E) is a small-molecule anticancer drug that might enter milk and be absorbed by the infant. The manufacturer recommends that breastfeeding be discontinued during enfortumab vedotin therapy and for at least 3 weeks after the last dose.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Substance Identification
Substance Name
Enfortumab
CAS Registry Number
1448664-46-7
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- LactMed App
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- Review Gemtuzumab Ozogamicin[Drugs and Lactation Database (...]Review Gemtuzumab Ozogamicin. Drugs and Lactation Database (LactMed). 2006
- Review Tafasitamab[Drugs and Lactation Database (...]Review Tafasitamab. Drugs and Lactation Database (LactMed). 2006
- Review Nivolumab[Drugs and Lactation Database (...]Review Nivolumab. Drugs and Lactation Database (LactMed). 2006
- Review Obinutuzumab[Drugs and Lactation Database (...]Review Obinutuzumab. Drugs and Lactation Database (LactMed). 2006
- Review Brentuximab Vedotin[Drugs and Lactation Database (...]Review Brentuximab Vedotin. Drugs and Lactation Database (LactMed). 2006
- Enfortumab Vedotin - Drugs and Lactation Database (LactMed)Enfortumab Vedotin - Drugs and Lactation Database (LactMed)
Your browsing activity is empty.
Activity recording is turned off.
See more...